138 related articles for article (PubMed ID: 35113414)
1. Risk factors of bone metastasis in patients with newly diagnosed prostate cancer.
Chaoying L; Chao M; Xiangrui Y; Yingjian H; Gang Z; Yunhan R; Yu G
Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):391-398. PubMed ID: 35113414
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients.
Peng C; Juan C; Mao W; Jinghe Y; Renli T
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3832-3839. PubMed ID: 35731052
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
4. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer].
Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z
Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321
[TBL] [Abstract][Full Text] [Related]
5. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
6. Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer.
Zou BZ; Wen H; Luo HJ; Luo WC; Xie QT; Zhou MT
Ir J Med Sci; 2023 Dec; 192(6):2681-2687. PubMed ID: 37414978
[TBL] [Abstract][Full Text] [Related]
7. [Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model].
Cheng Y; Luo LP; Hu S; Li LN; Wu C; Wu B; Wang DW
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):876-881. PubMed ID: 33113631
[No Abstract] [Full Text] [Related]
8. Age-specific prostate specific antigen cutoffs for guiding biopsy decision in Chinese population.
Na R; Wu Y; Xu J; Jiang H; Ding Q
PLoS One; 2013; 8(6):e67585. PubMed ID: 23825670
[TBL] [Abstract][Full Text] [Related]
9. Prediction of extraprostatic extension in patients with clinically organ-confined prostate cancer.
Lin S; Zhang Q; Li P; Li Z; Sun Y; Shao Y; Zhang X; Fu S
Urol Int; 2014; 92(3):282-8. PubMed ID: 24280781
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
12. Potential diagnostic value of multiple indicators combined with total prostate-specific antigen in prostate cancer.
Zhang Q; Li H; Song Z; Kong S; Zhao S; Fan S; Qin F; Ma J
J Int Med Res; 2023 Oct; 51(10):3000605231204429. PubMed ID: 37848343
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of prostate health index in predicting bone metastasis of prostate cancer before bone scanning.
Sun H; Zhu Y; Guo H; Jiang S; Guo H; Chen S
Int Urol Nephrol; 2022 Dec; 54(12):3079-3086. PubMed ID: 35987936
[TBL] [Abstract][Full Text] [Related]
14. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
15. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
16. LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer.
Inoue T; Kaneko T; Muramatsu S; Kimura H; Yoshino T; Goto T; Sawada A; Akamatsu S; Kobayashi T; Yamasaki T; Kaya T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e28-e36. PubMed ID: 31711843
[TBL] [Abstract][Full Text] [Related]
17. Clinical research analysis based on prostate cancer screening diagnosis.
Shan J; Geng X; Liu Z; Lu Y; Zhou R; Zhang Z; Xu H; Zhou X; Ma W; Zhu H; Shi H
Andrologia; 2022 May; 54(4):e14371. PubMed ID: 35014705
[TBL] [Abstract][Full Text] [Related]
18. Establishing a prediction model for prostate cancer bone metastasis.
Chen S; Wang L; Qian K; Jiang W; Deng H; Zhou Q; Wang G; Liu X; Wu CL; Xiao Y; Wang X
Int J Biol Sci; 2019; 15(1):208-220. PubMed ID: 30662360
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of serum isoform [-2] proprostate-specific antigen and its derivatives in predicting aggressive prostate cancer].
Sun KX; Yan CL; Li ZY; Liu P; Zhang W; He Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):234-239. PubMed ID: 32306004
[TBL] [Abstract][Full Text] [Related]
20. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
